Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from current and new leading global biotechnology investors Proceeds will support clinical evaluation of lead solid tumor ADC candidates, TUB-030 and TUB-040, further technology development and expansion into the US MUNICH, GERMANY, March 14, 2024 – Tubulis, a Fund+ portfolio company, today […]